Poly(ADP-ribose) Polymerase Inhibitors
"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
Descriptor ID |
D000067856
|
MeSH Number(s) |
D27.505.519.389.739 D27.505.954.248.692
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2009 | 3 | 2 | 5 |
2010 | 4 | 0 | 4 |
2011 | 8 | 2 | 10 |
2012 | 2 | 6 | 8 |
2013 | 2 | 1 | 3 |
2014 | 8 | 6 | 14 |
2015 | 6 | 2 | 8 |
2016 | 5 | 7 | 12 |
2017 | 12 | 12 | 24 |
2018 | 11 | 2 | 13 |
2019 | 20 | 5 | 25 |
2020 | 18 | 7 | 25 |
2021 | 18 | 5 | 23 |
2022 | 1 | 18 | 19 |
2023 | 5 | 15 | 20 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
DePARylation is critical for S phase progression and cell survival. Elife. 2024 Apr 05; 12.
-
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. J Clin Oncol. 2024 Apr 10; 42(11):1301-1310.
-
Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models. J Clin Invest. 2024 Jan 02; 134(1).
-
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023 12 19; 4(12):101326.
-
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res. 2023 11 01; 29(21):4464-4478.
-
A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proc Natl Acad Sci U S A. 2023 Oct 31; 120(44):e2307793120.
-
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecol Oncol. 2023 Nov; 178:161-169.
-
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20; 42(3):283-299.
-
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. Cancer Res Commun. 2023 10 16; 3(10):2096-2112.
-
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 10 03; 28(10):845-855.